Saturday 17 October 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.76
0.26
−8.61%
Follow ADXN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 2 | 3 | 4 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.76 | 0.00 |
Altman Z-Score |
— | — | — | — | (16.62) | (18.13) | (65.68) | (114.74) | (43.81) | (78.43) |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | 15.47 | 11.21 | 3.44 | 2.17 | 12.47 | 68.53 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (46.84) | (43.86) | (149.23) | (265.77) | (97.78) | (183.79) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | (1.09) | (1.77) | (5.44) | (0.36) | 5.79 |
P/Operating CF |
— | (7.03) | (7.03) | (7.03) | 58.52 | (10.92) | (1.51) | (6.94) | 73.32 | (10.13) |
P/B ratio |
— | 1.30 | 1.30 | 1.30 | 3.82 | 1.93 | 0.99 | 3.06 | 0.52 | 1.20 |
Price to Tangible BV |
— | 1.30 | 1.30 | 1.30 | 3.82 | 1.93 | 0.99 | 3.06 | 0.52 | 1.21 |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | 10.29 | 4.19 | (1.46) | (0.23) | 4.20 | 48.91 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.04 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.00 | 0.00 | 0.00 | (3.05) | (0.83) | 0.13 | 0.05 | (0.32) | (1.88) |
EV/FCF |
— | 0.00 | 0.00 | 0.00 | (3.04) | (0.83) | 0.13 | 0.05 | (0.32) | (1.88) |
Quick Ratio |
1.31 | 1.95 | 17.97 | 5.57 | 5.18 | 4.99 | 2.25 | 1.37 | 4.19 | 1.38 |
Current Ratio |
1.33 | 2.07 | 18.06 | 5.70 | 5.38 | 5.31 | 2.39 | 1.46 | 4.42 | 1.40 |
Net Debt/EBITDA |
0.44 | 0.80 | 29.31 | (11.69) | 1.58 | 1.35 | 0.34 | 0.39 | 1.34 | 0.58 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.62 | 0.00 | 0.00 | 0.33 | 0.14 | 0.09 | 0.26 | 0.05 | 0.00 |
Operating CF/Net income |
0.86 | 0.65 | (1.05) | 0.66 | 0.95 | 0.96 | 0.79 | 0.76 | (0.76) | 0.32 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | (0.16) | (0.09) | 0.00 | (0.02) | 0.00 | 0.00 |
Interest Coverage |
— | — | — | 73.10 | (18.82) | (246.23) | (65.50) | (30.34) | (782.42) | (180.70) |
| (389.80%) | (422.59%) | (8.11%) | (44.84%) | (65.47%) | (98.49%) | (184.19%) | (366.08%) | 130.66% | (96.99%) | |
| (129.31%) | (405.76%) | 0.00% | 0.00% | (118.36%) | (72.73%) | (130.77%) | (169.81%) | 92.65% | (81.98%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (27.18%) | (56.24%) |
Return on Tangible Assets |
(739.47%) | (207.71%) | (4.13%) | (52.90%) | (80.69%) | (85.87%) | (453.44%) | (773.95%) | 257.48% | (1,396.32%) |
Average Days of Receivables |
0.00 | 221.89 | 14.87 | 15.97 | 6.91 | 20.63 | 106.96 | 24.97 | 14.00 | 244.01 |
Research and Development Expense of Revenue |
0.00% | 523.58% | 73.35% | 451.86% | 287.13% | 440.30% | 1,030.99% | 431.65% | 211.42% | 2,239.50% |
Selling, General and Administrative Expense of Revenue |
0.00% | 220.50% | 47.86% | 182.19% | 159.13% | 199.52% | 513.18% | 307.87% | 571.90% | 7,721.55% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 32.56% | 40.40% | 258.85% | 111.25% | 124.47% | 236.19% |
Graham Net Nets |
— | 0.75 | 0.75 | 0.75 | 0.25 | 0.50 | 0.91 | 0.21 | 0.50 | 0.01 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52.95 | 0.00 |
Earnings Yield |
— | (8.15%) | (8.15%) | (8.15%) | (22.76%) | (45.31%) | (435.29%) | (230.00%) | 132.45% | (120.76%) |
Free Cash Flow Yield |
— | 0.00% | 0.00% | 0.00% | (21.90%) | (45.07%) | (336.96%) | (228.41%) | (106.66%) | (37.99%) |
Revenue per Share |
0.00 | 0.04 | 0.29 | 12.64 | 17.33 | 11.22 | 3.96 | 2.90 | 0.56 | 0.04 |
Operating CF per Share |
(0.23) | (0.17) | 0.08 | (44.86) | (58.41) | (56.57) | (45.75) | (14.38) | (7.46) | (2.93) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.29) | (0.12) | 0.00 | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.23) | (0.17) | 0.08 | (44.86) | (58.70) | (56.69) | (45.75) | (14.39) | (7.46) | (2.93) |
Cash per Share |
0.12 | 0.20 | 1.83 | 147.78 | 89.66 | 78.81 | 19.36 | 6.95 | 4.64 | 2.21 |
Shareholders Equity per Share |
0.02 | 0.11 | 1.72 | 119.61 | 70.07 | 65.13 | 13.67 | 2.06 | 13.44 | 6.43 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.02 | 0.11 | 1.72 | 119.61 | 70.07 | 65.13 | 13.67 | 2.06 | 13.44 | 6.43 |
Free Cash Flow |
(2.65) | (2.18) | 1.76 | (9.87) | (13.05) | (16.12) | (17.23) | (8.91) | (6.11) | (2.62) |
Working Capital |
0.40 | 1.61 | 40.63 | 27.53 | 16.93 | 19.48 | 4.76 | 1.49 | 3.11 | 0.58 |
Capital Expenditures |
(0.01) | 0.00 | (0.01) | (0.03) | (0.06) | (0.03) | 0.00 | (0.01) | 0.00 | — |
Net Current Asset Value |
0.19 | 1.36 | 39.98 | 25.65 | 14.84 | 17.87 | 4.67 | 0.82 | 2.89 | 0.10 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.04 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.49 | 5.43 | 0.33 | 0.58 | 5.51 | 4.82 | 7.86 | 13.52 | 227.31 | 11.33 |
Cash ROIC |
(165.22%) | (54.44%) | 2.13% | (16.78%) | (36.75%) | (39.39%) | (138.48%) | (159.63%) | (41.28%) | (33.90%) |
Accounts Receivable Turnover |
0.00 | 1.94 | 23.24 | 13.90 | 39.61 | 25.20 | 4.83 | 6.42 | 6.53 | 1.73 |
Accounts Payable Turnover |
0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — | — | — | — | — | — | — |
Average Days of Payables |
9,474.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | — | — | — | — | — |
Average Receivables |
0.26 | 0.26 | 0.29 | 0.20 | 0.10 | 0.13 | 0.31 | 0.28 | 0.07 | 0.02 |
Average Payables |
0.52 | 0.52 | 0.78 | 1.73 | 2.47 | 3.43 | 3.67 | 2.90 | 1.78 | 1.17 |
Average Assets |
2.39 | 0.82 | 0.00 | 0.00 | 11.59 | 23.09 | 16.67 | 6.92 | 8.65 | 9.91 |
Average Common Equity |
0.79 | 0.79 | 20.71 | 33.18 | 20.95 | 17.05 | 11.84 | 3.21 | 6.13 | 8.37 |
Columns are period end dates · fundamentals updated 30 Sep 2026